

The following **Listing of the Claims** will replace all prior versions and all prior listings of the claims in the present application:

**Listing of the Claims:**

1. (Canceled)
2. (Canceled)
3. (Currently Amended) A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient ~~in a once daily dose~~, wherein said once daily ~~dose~~ administration does not include a continuous administration or the presence of release rate-controlling agents.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
9. (Canceled)
10. (Currently Amended) The method according to claim 3, wherein ~~the~~ said C-peptide is human C-peptide
11. (Previously Presented) The method according to claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).
12. (Amended) The method according to claim 3, wherein ~~the~~ said patient is a human.
13. (Amended) The method according to claim 3, wherein ~~the said medicament~~ pharmaceutical composition contains 100 to 1800 nmol of C-peptide.
14. (Amended) The method according to claim 3, wherein ~~the said medicament~~ C-peptide is in an ~~uncompromised~~ aqueous solution.
15. (Previously Presented) The method according to claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.